{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:30Z","timestamp":1792788570171,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4t Ulm","id":[{"id":"https:\/\/ror.org\/032000t02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Persistence to oral anticoagulation (OAC) is crucial to prevent recurrent stroke in patients with atrial fibrillation (AF). Little is known about the association of OAC intake, persistence to OAC, and type of OAC with health-related quality of life (HRQoL) in stroke survivors with AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis of the multicenter Berlin Atrial Fibrillation Registry included 1,042 patients with acute ischemic stroke or transient ischemic attack (TIA) and AF. HRQoL data were measured at 3,12,24 and 36 months after stroke\/TIA using the EQ-5D-3\u00a0L questionnaire (including EQ-Index and EQ-VAS). Associations between OAC status, persistence to and type of OAC (direct oral anticoagulants (DOACs) against vitamin K antagonists (VKAs)) at 12 and up to 36 months with HRQoL were examined using multivariable linear models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 842 patients completed the 12-months follow-up and 437 patients the 36-months follow-up. After 12 months, OAC intake was associated with higher EQ-VAS scores (\u03b2\u2009=\u20096.70,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017), although this effect was not observed up to 36 months (\u00df= -3.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.075). Non-persistence to OAC was associated with lower EQ-VAS scores at 12 (\u00df= -6.25,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) and 36 months (\u00df= -5.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). No evidenve of a statistically significant difference in HRQoL was found between patients persistent to DOACs and those persistent to VKAs. EQ-Index values were not statistically significantly affected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Non-persistence to OAC was associated with reduced EQ-VAS up to 36 months after stroke. Notably, no evidence of a statistically significant difference regarding HRQOL was found between patients persistent on DOAC or VKA. Ensuring long-term persistence to OAC may support HRQoL in stroke survivors with AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-026-00534-z","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:09:25Z","timestamp":1789542565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of oral anticoagulation persistence and health-related quality of life in stroke survivors with atrial fibrillation: long-term results of the Berlin atrial fibrillation registry"],"prefix":"10.1186","volume":"8","author":[{"given":"Lena","family":"Steindorf-Sabath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel C.","family":"Olma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"T\u00fct\u00fcnc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Grittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jil","family":"Heege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Dietzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schurig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter U.","family":"Heuschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-5054","authenticated-orcid":false,"given":"Karl Georg","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"36","key":"534_CR1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder, I. C., et al. (2024). 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal, 45(36), 3314\u20133414.","journal-title":"European Heart Journal"},{"issue":"Fi1","key":"534_CR2","doi-asserted-by":"publisher","first-page":"f72","DOI":"10.1093\/ehjcvp\/pvaa017","volume":"7","author":"JJ Komen","year":"2021","unstructured":"Komen, J. J., et al. (2021). Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J Cardiovasc Pharmacother, 7(Fi1), f72\u2013f80.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"534_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/eurheartj\/ehx579","volume":"39","author":"L Friberg","year":"2018","unstructured":"Friberg, L., & Rosenqvist, M. (2018). Less dementia with oral anticoagulation in atrial fibrillation. European Heart Journal, 39(6), 453\u2013460.","journal-title":"European Heart Journal"},{"issue":"4","key":"534_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10557-020-06961-7","volume":"34","author":"X Liu","year":"2020","unstructured":"Liu, X., et al. (2020). Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies. Cardiovascular Drugs And Therapy, 34(4), 569\u2013578.","journal-title":"Cardiovascular Drugs And Therapy"},{"key":"534_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/DDDT.S45644","volume":"8","author":"H Mani","year":"2014","unstructured":"Mani, H., & Lindhoff-Last, E. (2014). New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug design development and therapy, 8, 789\u2013798.","journal-title":"Drug design development and therapy"},{"issue":"3","key":"534_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2217\/fca.14.13","volume":"10","author":"FA Ynsaurriaga","year":"2014","unstructured":"Ynsaurriaga, F. A., Peinado, R. P., Ormaetxe, J. M., & Merodio (2014). Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiology, 10(3), 381\u2013393.","journal-title":"Future Cardiology"},{"issue":"23","key":"534_CR7","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1136\/heartjnl-2019-316314","volume":"106","author":"P Krisai","year":"2020","unstructured":"Krisai, P., et al. (2020). Associations of symptoms and quality of life with outcomes in patients with atrial fibrillation. Heart, 106(23), 1847.","journal-title":"Heart"},{"key":"534_CR8","doi-asserted-by":"publisher","unstructured":"Chen Y et al. (2021). Association of patient-reported outcomes with hospitalization risk in atrial fibrillation. AmHeart J Plus. https:\/\/doi.org\/10.1016\/j.ahjo.2021.100007","DOI":"10.1016\/j.ahjo.2021.100007"},{"issue":"1","key":"534_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12955-023-02112-2","volume":"21","author":"L Theunissen","year":"2023","unstructured":"Theunissen, L., et al. (2023). The prognostic value of quality of life in atrial fibrillation on patient value. Health And Quality Of Life Outcomes, 21(1), 33.","journal-title":"Health And Quality Of Life Outcomes"},{"issue":"12","key":"534_CR10","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1111\/bcp.13985","volume":"85","author":"SK Afzal","year":"2019","unstructured":"Afzal, S. K., Hasan, S. S., & Babar, Z. U. (2019). A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants. British Journal Of Clinical Pharmacology, 85(12), 2652\u20132667.","journal-title":"British Journal Of Clinical Pharmacology"},{"issue":"1","key":"534_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/16078454.2021.1892329","volume":"26","author":"M Gabilondo","year":"2021","unstructured":"Gabilondo, M., et al. (2021). Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Hematology, 26(1), 277\u2013283.","journal-title":"Hematology"},{"key":"534_CR12","doi-asserted-by":"crossref","unstructured":"Cabanas-Grand\u00edo, P. et al. (2024). Health-Related Quality of Life and Satisfaction in Atrial Fibrillation Patients on Anticoagulant Therapy: Differences between Vitamin K Antagonists and Direct Oral Anticoagulants; Results from the Multicentre REGUEIFA Registry. J Clin Med, 13(17).","DOI":"10.20944\/preprints202406.0389.v1"},{"issue":"1","key":"534_CR13","doi-asserted-by":"publisher","first-page":"e70248","DOI":"10.1002\/brb3.70248","volume":"15","author":"MC Olma","year":"2025","unstructured":"Olma, M. C., et al. (2025). The Role of Atrial Fibrillation and Oral Anticoagulation Status in Health-Related Quality of Life 12 Months After Ischemic Stroke or TIA. Brain and Behavior, 15(1), e70248.","journal-title":"Brain and Behavior"},{"issue":"11","key":"534_CR14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/europace\/euz199","volume":"21","author":"KG Haeusler","year":"2019","unstructured":"Haeusler, K. G., et al. (2019). Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry. Europace, 21(11), 1621\u20131632.","journal-title":"Europace"},{"issue":"2","key":"534_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10198-004-0264-z","volume":"6","author":"W Greiner","year":"2005","unstructured":"Greiner, W., et al. (2005). Validating the EQ-5D with time trade off for the German population. The European Journal of Health Economics, 6(2), 124\u2013130.","journal-title":"The European Journal of Health Economics"},{"key":"534_CR16","unstructured":"EuroQol, R., & Foundation (2018). EQ-5D-3L-User-Guide Version 6.0. Basic information on how to use the EQ-5D-3L instrument."},{"issue":"10","key":"534_CR17","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s11136-019-02248-z","volume":"28","author":"BD Rapkin","year":"2019","unstructured":"Rapkin, B. D., & Schwartz, C. E. (2019). Advancing quality-of-life research by deepening our understanding of response shift: a unifying theory of appraisal. Quality Of Life Research, 28(10), 2623\u20132630.","journal-title":"Quality Of Life Research"},{"key":"534_CR18","doi-asserted-by":"crossref","unstructured":"Zortea, V., et al. (2023). Adherence and Quality of Life in Non-Valvular Atrial Fibrillation With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review. International Journal of Cardiovascular Sciences, 36, \u2013.","DOI":"10.36660\/ijcs.20220115"},{"issue":"1","key":"534_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12955-020-01563-1","volume":"18","author":"JF Varona","year":"2020","unstructured":"Varona, J. F., et al. (2020). Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status. Health And Quality Of Life Outcomes, 18(1), 383.","journal-title":"Health And Quality Of Life Outcomes"},{"issue":"7","key":"534_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1185\/030079905X50624","volume":"21","author":"P Casais","year":"2005","unstructured":"Casais, P., et al. (2005). Patients\u2019 perceptions regarding oral anticoagulation therapy and its effect on quality of life. Current Medical Research And Opinion, 21(7), 1085\u20131090.","journal-title":"Current Medical Research And Opinion"},{"issue":"10","key":"534_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.4070\/kcj.2019.0234","volume":"49","author":"N Lowres","year":"2019","unstructured":"Lowres, N., et al. (2019). Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. Korean Circ J, 49(10), 883\u2013907.","journal-title":"Korean Circ J"},{"issue":"6","key":"534_CR22","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s11136-015-1196-z","volume":"25","author":"P Chen","year":"2016","unstructured":"Chen, P., et al. (2016). Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation. Quality Of Life Research, 25(6), 1585\u20131596.","journal-title":"Quality Of Life Research"},{"issue":"13","key":"534_CR23","doi-asserted-by":"publisher","first-page":"e024296","DOI":"10.1161\/JAHA.121.024296","volume":"11","author":"RA Joundi","year":"2022","unstructured":"Joundi, R. A., et al. (2022). Health State Utility Values in People With Stroke: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 11(13), e024296.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"534_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11136-021-02944-9","volume":"31","author":"LJ Cameron","year":"2022","unstructured":"Cameron, L. J., et al. (2022). Self-reported quality of life following stroke: a systematic review of instruments with a focus on their psychometric properties. Quality Of Life Research, 31(2), 329\u2013342.","journal-title":"Quality Of Life Research"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-026-00534-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:09:30Z","timestamp":1789542570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42466-026-00534-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1186\/s42466-026-00534-z","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"13 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Berlin Atrial Fibrillation Registry received approval by the ethics committees of all participating sites, with initial approval by the Charit\u00e9 Ethics Committee, Berlin, Germany (EA2_033_14). All study patients provided written informed consent, and when the study follow-up was extended to 36 months, all participants were required to give renewed consent to continue to the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"78"}}